Organized by Donald Mastronarde, Professor of the Graduate School, Emeritus Melpomene Distinguished Professor of Classical Languages and
Literature
Carol D’Onofrio was Chair of the UCB Retirement Center Board from 2009-2011 and served as a member at large from 2006-08. She served on the Learning in Retirement Committee for many years, chairing the committee in 2017-2019. Carol passed away on April 14, 2020.
PART I: COVID-19: Where Have We Been and Where Are We Going?
Tuesday, April 5th, 2022, 2pm Pacific Time
Speaker: Arthur Reingold, MD, Professor of Epidemiology, UC Berkeley
CLICK HERE TO REGISTER
PART II: Improving the "Relevance, Rigor and Reach" of Research through Engaging Communities: Case Studies from San Francisco's Chinatown and Tenderloin Neighborhoods
Tuesday, April 12th, 2022, 2pm Pacific Time
Speaker: Meredith Minkler, Professor of the Graduate School, Professor Emerita of Public Health, UC Berkeley.
Topic Description: A growing body of evidence has demonstrated the value of engaging communities in both improving the quality of the research itself and translating findings into actionable change on the community through the policy levels to address some of our most intractable health and social problems. This presentation will briefly discuss the genesis and principles of community-engaged research, and its wide use today to study and address health inequities, and then illustrate its efficacy and outcomes using two case studies. The examples are from collaborations between UC Berkeley's School of Public Health, colleagues in the SF Department of Public Health, and community groups in SF's Chinatown and Tenderloin communities respectively.
CLICK HERE TO REGISTER
PART III: Alzheimer's Disease: What is it, and Can we Treat it?
Tuesday, April 19th, 2022, 2pm Pacific Time
Speaker: William Jagust MD, Professor of Public Health and Neuroscience, UC Berkeley.
Topic Description: This talk will review current concepts of what Alzheimer's disease is - how it develops in the brain and how it causes symptoms. The past year has also seen the approval of a very controversial new therapy, Aducanumab, which targets amyloid deposits in the brain. The rationale for this treatment approach will be discussed in the context of what we understand about Alzheimer's disease and the potential benefits and drawbacks of ongoing and planned therapeutic trials.
CLICK HERE TO REGISTER